Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Gynecologic Oncology

Life After Treatment: Long-Term Side Effects and Survivorship

At a Glance

After cervical squamous cell carcinoma treatment, lifelong follow-up helps detect recurrence and manage late effects such as vaginal narrowing, bowel or bladder changes, lymphedema, neuropathy, early menopause, and second HPV-related cancers.

Completing treatment for cervical squamous cell carcinoma (SCC) is a significant milestone, but it also marks the beginning of a new phase: survivorship. This stage involves monitoring for the cancer’s return and managing the long-term effects that treatment can leave on your body.

While the first few years are the most critical for monitoring, survivorship is a lifelong commitment to your health and well-being [1].

Monitoring for Recurrence

The goal of follow-up care is to find any recurrence as early as possible. For the first two years, you will likely see your doctor every 3 to 4 months [1]. After that, visits usually spread out to every 6 to 12 months through the fifth year [1].

  • Imaging: Many patients have a post-treatment response scan (like a PET/CT or MRI) about 3 to 6 months after finishing definitive chemoradiation [2]. After that, you will not typically have routine PET or CT scans if you have no symptoms, as imaging is often symptom-driven [1].
  • The Power of the Exam: In cervical cancer, a physical exam and a review of your symptoms are critical. Routine “vaginal cuff” Pap smears have a limited ability to detect recurrence after radiation, though their use varies by clinic protocol [3][4].
  • Report Symptoms: Never wait for a scheduled scan if you develop new pain, bleeding, or other concerning symptoms. Report any new bleeding or pain immediately, even if a Pap result was normal.

Managing Long-Term Vaginal Health

Radiation therapy can cause the tissues of the vagina to become thinner, drier, and less elastic. Over time, this can lead to vaginal stenosis, where the vagina becomes shorter or narrower due to the formation of scar tissue (fibrosis) [5][6].

  • Vaginal Dilation: Using a vaginal dilator (a smooth plastic or silicone tube) can help keep the vaginal walls flexible and prevent them from sticking together [6]. Your team will tell you when it is safe to start (usually a few weeks after healing from brachytherapy). Use plenty of lubrication, and stop if you experience severe pain, bleeding, or suspect an infection [7].
  • It Must Be Safe: While regular sexual activity can help some patients, sex should never be treated as a mandatory “prescription” if it is painful.
  • Lubricants and Estrogen: For dryness and discomfort, your doctor may recommend high-quality vaginal moisturizers or topical estrogen (creams or rings) that act locally to strengthen the vaginal lining without affecting the rest of your body [8][9].

Late Effects of Radiation: Bowel and Bladder

Some side effects from radiation do not appear until months or even years after treatment ends.

  • Radiation Proctitis: This is inflammation of the rectum that can cause bleeding, a frequent urge to go, or diarrhea [10]. While these symptoms often appear within the first year, they can occasionally emerge up to a decade later [10].
  • Radiation Cystitis: This affects the bladder lining and may cause blood in the urine, urgency, or recurrent infections [11][12].

It is vital to report any new rectal or urinary bleeding to your care team. These are often manageable late effects, but they require a medical evaluation to rule out recurrence or other causes [10].

Lymphedema and Neuropathy

  • Lymphedema: If you had lymph nodes removed or received radiation, you are at risk for lymphedema, a chronic swelling caused by a buildup of lymph fluid [13]. This most often affects the legs, groin, or pelvic area [14]. Early signs include a feeling of “heaviness” or skin that feels tight. Specialized complex decongestive therapy (CDT), which includes massage and compression garments, is the standard treatment [15][16].
  • Neuropathy: Chemotherapy (especially cisplatin) can cause lingering numbness, tingling, or “pins and needles” in your hands or feet [17]. Physical therapy and certain medications can help manage these symptoms if they interfere with your daily life.

Hormone Health and Menopause

If you were premenopausal before treatment, pelvic radiation often causes premature ovarian insufficiency (POI), or early menopause [17]. If your ovaries were surgically moved higher in the abdomen (ovarian transposition) before radiation, they may continue to function for a time, but many women will still experience menopause sooner than expected [18].

Hormone Replacement Therapy (HRT) can be an effective way to manage hot flashes, protect your bone health, and support your sexual health [8][19]. Because cervical SCC is not typically sensitive to hormones, many survivors are good candidates for HRT. However, this choice must be highly individualized based on your age, cardiovascular history, clotting risks, and whether your uterus remains (systemic estrogen generally requires progestogen when a uterus is present) [19][20].

Looking Toward the Future: Second Cancers

Survivors of HPV-related cervical cancer have a slightly higher risk of developing other HPV-related cancers later in life, such as anal, vulvar, or oropharyngeal (throat) cancers [21][22].

  • Anal Health: Risk for anal cancer may persist or even increase 10 to 20 years after your diagnosis [21][22]. Some experts now recommend discussing anal cancer screening (similar to a Pap smear but for the anus) for cervical cancer survivors, based on your risk factors and local clinical guidelines. If abnormal, this requires access to specialized follow-up (high-resolution anoscopy) [23].
  • Prevention: If you smoke, quitting is the single most important step you can take to lower your risk of these second cancers [24][25]. Smoking acts as a “gasoline” to the “fire” of HPV, making it much more likely that the virus will cause new cellular changes [24].

Survivorship is about more than just checking for cancer; it is about reclaiming your quality of life. By staying proactive and communicating openly with your care team, you can manage these long-term effects and focus on your future [26].

Common questions in this guide

How often will I need follow-up visits after cervical SCC treatment?
Follow-up is often every 3 to 4 months during the first two years, then every 6 to 12 months through the fifth year. Your clinician will adjust this schedule based on your treatment and symptoms. Lifelong attention to new symptoms remains important.
Do I need regular scans or Pap tests after cervical cancer treatment?
Many patients have a PET/CT or MRI about 3 to 6 months after completing chemotherapy and radiation to assess treatment response. If you have no symptoms, routine PET or CT scans are not usually done afterward; physical exams and symptom review remain central. Pap tests from the top of the vagina may have limited ability to detect recurrence after radiation, so report new bleeding or pain even after a normal result.
What can I do about vaginal dryness or narrowing after radiation?
Pelvic radiation can make vaginal tissues thinner, drier, and less flexible, sometimes causing scarring and narrowing called vaginal stenosis. Once your treatment team confirms healing, a vaginal dilator, adequate lubricant, moisturizers, or sometimes local vaginal estrogen may help. Stop and seek advice for severe pain, bleeding, or possible infection, and sex should not be required if it hurts.
Could bowel or urinary symptoms years later be caused by radiation?
Radiation proctitis can cause rectal bleeding, urgency, or diarrhea, while radiation cystitis can cause blood in the urine, urgency, or repeated infections. These effects may appear months or years after treatment. New rectal or urinary bleeding needs prompt medical assessment to distinguish a late effect from recurrence or another cause.
How are lymphedema and chemotherapy-related numbness treated?
Removal of lymph nodes or pelvic radiation can lead to chronic swelling in the legs, groin, or pelvis; heaviness and tight skin may be early signs. Complex decongestive therapy, including specialized massage and compression garments, is a standard treatment. Numbness or tingling from chemotherapy such as cisplatin may improve with physical therapy or medicines when it disrupts daily activities.
Is hormone replacement therapy safe after cervical SCC?
Cervical squamous cell carcinoma is not typically sensitive to hormones, so many survivors may be candidates for hormone replacement therapy or local vaginal estrogen. The decision depends on age, heart and blood-vessel health, clotting risk, symptoms, and whether the uterus remains; systemic estrogen generally needs a progestogen if the uterus is present. Discuss the choice with your clinician rather than starting hormones on your own.
Should I ask about anal cancer screening after cervical cancer?
People treated for HPV-related cervical cancer have a higher risk of some other HPV-related cancers, including anal cancer. Ask your clinician whether anal screening is appropriate for you based on your risk factors and local guidance. An abnormal screening result may require high-resolution anoscopy, a specialized examination of the anus.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the specific plan for my post-treatment response scan, and how will we monitor me after that?
  2. 2.Can you provide detailed instructions on when it is safe to begin using a vaginal dilator and how often I should use it?
  3. 3.Are my symptoms—such as rectal bleeding or urinary urgency—related to late radiation effects like proctitis or cystitis?
  4. 4.Given my medical history, am I a safe candidate for hormone replacement therapy (HRT) or local vaginal estrogen?
  5. 5.Should we discuss anal cancer screening based on my risk factors and our local clinical guidelines?
  6. 6.What signs of lymphedema should I be watching for in my legs or pelvic area, and can I be referred to a lymphedema therapist?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (26)
  1. 1

    Follow-up for cervical cancer: a Program in Evidence-Based Care systematic review and clinical practice guideline update.

    Elit L, Kennedy EB, Fyles A, Metser U

    Current oncology (Toronto, Ont.) 2016; (23(2)):109-18 doi:10.3747/co.23.2742.

    PMID: 27122975
  2. 2

    Current imaging strategies for the evaluation of uterine cervical cancer.

    Bourgioti C, Chatoupis K, Moulopoulos LA

    World journal of radiology 2016; (8(4)):342-54 doi:10.4329/wjr.v8.i4.342.

    PMID: 27158421
  3. 3

    Diagnostic Strategies for Recurrent Cervical Cancer: A Cohort Study.

    Chao X, Fan J, Song X, et al.

    Frontiers in oncology 2020; (10()):591253 doi:10.3389/fonc.2020.591253.

    PMID: 33365270
  4. 4

    Utility of routine cytology in detecting asymptomatic cervical cancer recurrence.

    McDowell JL, Young AJ, Daucher JA, Purinton SC

    Journal of the American Society of Cytopathology 2022; (11(3)):173-179 doi:10.1016/j.jasc.2021.12.004.

    PMID: 35074286
  5. 5

    Dose-effect relationship between vaginal dose points and vaginal stenosis in cervical cancer: An EMBRACE-I sub-study.

    Westerveld H, Kirchheiner K, Nout RA, et al.

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2022; (168()):8-15 doi:10.1016/j.radonc.2021.12.034.

    PMID: 35063582
  6. 6

    Association Between the Regular Use of Vaginal Dilators and/or Sexual Activity and Vaginal Morbidity in Locally Advanced Cervical Cancer Survivors: An EMBRACE-I Study Report.

    Kirchheiner K, Zaharie A, Smet S, et al.

    International journal of radiation oncology, biology, physics 2025; (121(2)):452-464 doi:10.1016/j.ijrobp.2024.09.011.

    PMID: 39278418
  7. 7

    Dose-effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study.

    Kirchheiner K, Nout RA, Lindegaard JC, et al.

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2016; (118(1)):160-6.

    PMID: 26780997
  8. 8

    Hormone Replacement Therapy in Patients with Gynecologic Cancer and Radiation-Induced Premature Ovarian Insufficiency.

    Pepin A, Chesnokova A, Pishko A, et al.

    International journal of radiation oncology, biology, physics 2025; (121(4)):1042-1052 doi:10.1016/j.ijrobp.2024.10.023.

    PMID: 39448037
  9. 9

    2024 SOGC, 2024 NCCN, 2022 ESO-ESMO, and 2018 ASCO: a comparison of female cancer survivorship guidelines for the management of sexual health concerns.

    Bhinder JK, Kennedy SKF, Faouk Al Aadah C, Al-Khaifi M

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2025; (33(7)):584 doi:10.1007/s00520-025-09640-1.

    PMID: 40518469
  10. 10

    Socioeconomic status as an independent risk factor for severe late bowel toxicity after primary radiotherapy for cervical cancer.

    Laan JJ, van Lonkhuijzen LRCW, van Os RM, et al.

    Gynecologic oncology 2017; (147(3)):684-689 doi:10.1016/j.ygyno.2017.10.013.

    PMID: 29074259
  11. 11

    Risk Factors for Ureteral Stricture After Radiochemotherapy Including Image Guided Adaptive Brachytherapy in Cervical Cancer: Results From the EMBRACE Studies.

    Fokdal L, Tanderup K, Pötter R, et al.

    International journal of radiation oncology, biology, physics 2019; (103(4)):887-894 doi:10.1016/j.ijrobp.2018.11.006.

    PMID: 30419309
  12. 12

    The impact of bladder volume on dosimetric outcomes in VMAT for cervical cancer patients after surgery.

    Wang Y, Wang M, Zhu L

    Journal of gynecologic oncology 2025; (36(4)):e65 doi:10.3802/jgo.2025.36.e65.

    PMID: 40223551
  13. 13

    Risk factors for lower limb lymphedema after gynecological cancer treatment: a systematic review.

    Decorte T, Cerckel M, Kheir GB, et al.

    Frontiers in oncology 2025; (15()):1561836 doi:10.3389/fonc.2025.1561836.

    PMID: 40463868
  14. 14

    Incidence, prevalence, and factors associated with lymphedema after treatment for cervical cancer: a systematic review.

    Bona AF, Ferreira KR, Carvalho RBM, et al.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2020; (30(11)):1697-1704 doi:10.1136/ijgc-2020-001682.

    PMID: 32863276
  15. 15

    How to Care and Minimize the Sequelae of Lower Extremity Lymphedema.

    Bobrek K, Nabavizadeh R, Nabavizadeh B, Master V

    Seminars in oncology nursing 2022; (38(3)):151270 doi:10.1016/j.soncn.2022.151270.

    PMID: 35431083
  16. 16

    Effectiveness of modified complex decongestive physiotherapy for preventing lower extremity lymphedema after radical surgery for cervical cancer: a randomized controlled trial.

    Wang X, Ding Y, Cai HY, et al.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2020; (30(6)):757-763 doi:10.1136/ijgc-2019-000911.

    PMID: 32107315
  17. 17

    Patient experiences of radiation-induced menopause in cervical cancer: A scoping review.

    Jacques LJ, Clarkson M, Humphrey PM

    Radiography (London, England : 1995) 2026; (32(3)):103345 doi:10.1016/j.radi.2026.103345.

    PMID: 41679255
  18. 18

    Ovarian damage from chemotherapy and current approaches to its protection.

    Spears N, Lopes F, Stefansdottir A, et al.

    Human reproduction update 2019; (25(6)):673-693 doi:10.1093/humupd/dmz027.

    PMID: 31600388
  19. 19

    HRT for women with premature ovarian insufficiency: a comprehensive review.

    Webber L, Anderson RA, Davies M, et al.

    Human reproduction open 2017; (2017(2)):hox007 doi:10.1093/hropen/hox007.

    PMID: 30895225
  20. 20

    Long-term health consequences of premature or early menopause and considerations for management.

    Faubion SS, Kuhle CL, Shuster LT, Rocca WA

    Climacteric : the journal of the International Menopause Society 2015; (18(4)):483-91 doi:10.3109/13697137.2015.1020484.

    PMID: 25845383
  21. 21

    Second primary anal and oropharyngeal cancers in cervical cancer survivors.

    Papatla K, Halpern MT, Hernandez E, et al.

    American journal of obstetrics and gynecology 2019; (221(5)):478.e1-478.e6 doi:10.1016/j.ajog.2019.05.025.

    PMID: 31128108
  22. 22

    Incidences and risk factors of metachronous vulvar, vaginal, and anal cancers after cervical cancer diagnosis.

    Matsuo K, Blake EA, Machida H, et al.

    Gynecologic oncology 2018; (150(3)):501-508 doi:10.1016/j.ygyno.2018.07.016.

    PMID: 30054103
  23. 23

    International Anal Neoplasia Society's consensus guidelines for anal cancer screening.

    Stier EA, Clarke MA, Deshmukh AA, et al.

    International journal of cancer 2024; (154(10)):1694-1702 doi:10.1002/ijc.34850.

    PMID: 38297406
  24. 24

    Second primary malignancies in cervical cancer and endometrial cancer survivors: a population-based analysis.

    Huang K, Xu L, Jia M, et al.

    Aging 2022; (14(9)):3836-3855 doi:10.18632/aging.204047.

    PMID: 35507749
  25. 25

    Smoking Cessation Treatment Needs of Low SES Cervical Cancer Survivors.

    Hoover DS, Spears CA, Vidrine DJ, et al.

    American journal of health behavior 2019; (43(3)):606-620 doi:10.5993/AJHB.43.3.14.

    PMID: 31046890
  26. 26

    GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee.

    Woopen H, Sehouli J, Davis A, et al.

    Cancer treatment reviews 2022; (107()):102396 doi:10.1016/j.ctrv.2022.102396.

    PMID: 35525106

This cervical cancer survivorship page is for informational purposes only and does not constitute medical advice. Speak with your oncology team about new symptoms and individualized follow-up or treatment decisions.

Get notified when new evidence is published on Squamous cell carcinoma of the cervix uteri.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.